Volvoman,
Washer sums it up when he mentions the companies in clinical let alone preclinical phase commanding hundreds of millions in market cap.
Brilliant innovative technology
Scaleable allogenic nature.
Keen to partner off for diseases.
Multibagger in the making. 2014 or after the consolidation is the thing.
List pricing is also a potential risk (probably to upside i tend to think in light of washer history)
